
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodie... Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.75 | 4.2111173498 | 17.81 | 21.03 | 17.24 | 835052 | 19.36630003 | CS |
4 | -3.79 | -16.9574944072 | 22.35 | 23.75 | 17.24 | 673523 | 20.39856613 | CS |
12 | -5.66 | -23.3691164327 | 24.22 | 26.01 | 17.24 | 604843 | 21.86664219 | CS |
26 | -9.54 | -33.9501779359 | 28.1 | 40.26 | 17.24 | 589151 | 26.21542921 | CS |
52 | -18.5 | -49.9190501889 | 37.06 | 47.97 | 17.24 | 533388 | 28.4990441 | CS |
156 | 7.75 | 71.6928769658 | 10.81 | 47.97 | 10.42 | 495409 | 28.13295329 | CS |
260 | 7.75 | 71.6928769658 | 10.81 | 47.97 | 10.42 | 495409 | 28.13295329 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions